2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

10.1002/art.23721

10.1016/j.jamcollsurg.2005.07.009

10.1177/0272989X04264212

10.1016/S0895-4356(01)00365-1

Singh JA, 2010, Golimumab for rheumatoid arthritis, Cochrane Database Syst Rev, 1, CD008341

Singh JA, 2010, Tocilizumab for rheumatoid arthritis, Cochrane Database Syst Rev, 7, CD008331

Singh JA, 2009, Biologics for rheumatoid arthritis: an overview of Cochrane reviews, Cochrane Database Syst Rev, 4, CD007848

Ruiz Garcia V, 2009, Certolizumab pegol (CDP870) for rheumatoid arthritis in adults, Cochrane Database Syst Rev, 2, CD007649

10.2307/2529310

FDA US Department of Health and Human Services. What is a serious adverse event?2011. URL:http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm.

Hunt SA, 2005, ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society, Circulation, 112, e154

10.1002/hep.1840040313

10.1002/clc.4960220604

CDC, 2000, Targeted tuberculin testing and treatment of latent tuberculosis infection, MMWR Mortal Morb Wkly Rep, 49, 1

10.1002/art.24106

10.1016/S0140-6736(08)61000-4

10.1002/art.23541

Kimel M, 2008, Adalimumab plus methotrexate improved SF‐36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA, J Rheumatol, 35, 206

10.1002/art.21661

10.1002/art.20568

10.1136/ard.2008.093294

10.1056/NEJM200011303432201

10.1002/art.27584

10.1002/art.1780310302

10.1136/ard.2009.126532

10.1016/j.rdc.2005.09.005

10.1002/art.21235

10.1002/art.1780380602

Pincus T, 2005, The American College of Rheumatology (ACR) core data set and derivative “patient only” indices to assess rheumatoid arthritis, Clin Exp Rheumatol, 23, S109

Wells GA, 2005, Minimal disease activity for rheumatoid arthritis: a preliminary definition, J Rheumatol, 32, 2016

Wolfe F, 2005, A composite disease activity scale for clinical practice, observational studies, and clinical trials: the Patient Activity Scale (PAS/PAS‐II), J Rheumatol, 32, 2410

10.1002/art.21494

10.1007/s10067-006-0275-5

10.1007/s10067-006-0343-x

10.1136/ard.2005.041376

10.1136/ard.62.2.120

10.1136/ard.62.5.427

10.1136/ard.36.1.71

10.1136/ard.2007.084459

Bresnihan B, 2002, Preventing joint damage as the best measure of biologic drug therapy, J Rheumatol Suppl, 65, 39

10.1002/art.30129

10.1016/j.berh.2007.02.005

10.1186/ar1740

10.1002/art.11407

10.1093/rheumatology/keg072